^
Association details:
| Biomarker: | ALK fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | ALK inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
ALK inhibitors are recommended for patients with metastatic NSCLC who are positive for ALK fusions.
